Cadrenal Therapeutics: Baggett reports 7.3% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cadrenal Therapeutics, Inc. (CVKD) common stock is the subject of Investor Ben Baggett’s reported beneficial ownership of 300,000 shares, or 7.3% of the class. He reported sole voting and dispositive power over 300,000 shares, with zero shared power in either category.
Key Figures
Key Terms
beneficially owned technical
sole voting power technical
sole dispositive power technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.